EVM (European Vaccine Manufacturers)
http://www.efpia.org/1_efpia/evm/evm.htm
What
is EFPIA?
Mission
statement
Activities
and accomplishments
Structure
and organisation
Your
direct contact in the secretariat
Membership
EBE
(Emerging Biopharmaceutical Enterprises)
EVM
(European Vaccine Manufacturers)
European Vaccine Manufacturers
(EVM) is a specialised group
created within EFPIA (European Federation
of Pharmaceutical Industries and
Associations) in 1991 in order
to define and convey the industry's views
on vaccine-related issues to public
health and regulatory
authorities.
On this page you will find the EVM
fact sheets, as well as
information on EVM objectives, achievements
and membership. If you would like
to know more about vaccination
and the perspectives for the European
vaccine manufacturers, click here.
Please also note that EVM is
organising its 5th Conference on
Vaccinology, "A Safe Future with
Vaccination", from 21 to 23
March 2001 in Lucerne, Switzerland.
For details about this conference click
here.
For further information, please
contact:
Kathleen Vandendael - EVM Executive
Manager
Telephone: 32.2.626.25.47
Fax: 32.2.626.25.66
E-mail: kathleenvandendael@efpia.org
You are visitor number since
04 December 2000 - please bookmark
this page for ease of access
in the future.
EVM Fact Sheets
Below are EVM's most recent fact
sheets, giving its views on
current issues of interest:
Vaccination
among the elderly - Flu, pneumonia, tetanus
Vaccine
development: from laboratory to market and beyond
Influenza
UK
vaccination campaign with new meningococcal conjugate
vaccines
Prevention
of Measles, Mumps and Rubella
The
recurrence of certain infectious diseases linked to a
fall in vigilance
Travel
and Hepatitis
Vaccination:
success and perspectives
I. EVM Objectives
To promote a favourable climate for
improved vaccine protection
and coverage as well as for the sustained
innovative capability of the
European vaccine industry by:
creating
a more supportive regulatory environment;
raising
public and health authorities' awareness of what can
be achieved worldwide with vaccines
and
of new developments in this field;
supporting
relationships with European and international
bodies;
stimulating
research and development through:
dialogue
with and the support of the European Commission;
the
creation of a favourable environment for the
development of new technologies in the field
of
vaccination by universities and other academic
institutions.
II. EVM Achievements
Recognition
of EVM as an organisation representing a
specific sector of the pharmaceutical
industry;
Creation
of working groups to raise vaccine-related issues
with European institutions;
Drafting
of position papers for discussion and review with
the appropriate authorities and audiences;
Four
European Conferences:
Annecy,
1992: "Vaccines for the World: the European
Contribution"
Brussels,
1994: "Combined Vaccines for Europe:
Pharmaceutical, Regulatory and
Policy-Making
Aspects"
Berlin,
1996: "Building Lifelong Immunity"
Brighton,
1999: "Societal Value of Vaccination"
III. Membership
BAXTER-IMMUNO - Austria
BERNA - Switzerland
CHIRON VACCINES - Italy &
Germany
MEDEVA - United Kingdom
AVENTIS PASTEUR MSD - France
SMITHKLINE BEECHAM BIOLOGICALS -
Belgium
WYETH-LEDERLE VACCINES - Belgium
IV. Characteristics of EVM Members
1.Significant
investment in innovative research and development
2.Full range of
vaccines
3.High-quality
standards
4.EVM member companies
together produce more than 1.5 billion
doses annually
5.Major suppliers of
vaccines used worldwide, producing
two-thirds of the vaccines used by UNICEF
V. Why is vaccination gaining
interest every day?
Every year, infectious diseases
cause illness or death in
millions of people. Vaccination can prevent much
of this suffering and death and
improve quality of life.
Vaccination is one of the most
cost-effective health
interventions around and it remains a key means of
preventing infectious diseases and
improving health throughout
the world.
VI. Vaccine protection for all
Childhood
vaccination programmes are essential weapons in
the battle against infectious diseases,
such
as Diphtheria, Poliomyelitis, Tetanus, Pertussis,
Hepatitis B, Heamophilus influenzae type bn
Meningitis,
Measles, Mumps, Rubella and Tuberculosis.
Vaccination
can reduce the risk of serious infections for
adolescents and adults from diseases
including
Hepatitis A, Hepatitis B, Influenza and
Pneumococcal diseases, as well as maintain
immunity
from previous vaccination by regular boosters.
Certain
vaccine-preventable diseases (e.g. Tuberculosis and
Pneumonia) are re-emerging due to
epidemiological
changes and increased resistance to
antibiotics. Vaccination policies therefore
need
to be revised and implemented.
Coinciding
with the recent changes in social structures in
Eastern Europe caused by war and civil
disturbance,
there has been a recurrence in diseases such as
Diphtheria and Poliomyelitis. High
vaccination
coverage rates are needed to prevent the risk of
infection and further transmission
across
Europe.
People
living in tropical countries or specific high-risk
areas and visitors to such regions should be
protected
against a wide range of vaccine-preventable
diseases such as Typhoid, Yellow Fever,
Hepatitis
A, Hepatitis B, Tick-Borne Encephalitis,
Diphtheria, Poliomyelitis, and Tetanus.
Occupational
or professional risks may be reduced or
eliminated by immunisation against certain
diseases
such as Hepatitis A, Hepatitis B and Rabies.
VII. Future perspectives for the
European vaccine industry
EVM members are working to combat
infectious diseases and
continue to explore and adapt new
biotechnology processes to improve
vaccines by:
Ensuring
that vaccines of a consistently high quality,
safety and efficacy are continuously produced.
Member
companies offer a comprehensive range of vaccines for
worldwide use, either as single
antigens
or as combined vaccines.
Improving
current vaccines and developing innovative
approaches to delivery. Much effort is being
devoted
to combining certain antigens so as to simplify the
administration of multiple vaccines for all
age
groups.
Developing
new vaccines to meet public health needs in
combating diseases such as Hepatitis C,
Herpes,
Otitis Media, Meningitis A, B, C, AIDS, Lyme
Disease, Malaria, Papilloma Virus, RSV,
PIV,
Helicobacter Pylori and Zoster. This activity
represents a major investment by member
companies.
Researching
and developing therapeutic applications of
existing and future vaccines for conditions
such
as chronic infectious diseases and certain forms of
cancer.
© Efpia 1999-2000